In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Vyome Holdings, with a price target of $15.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Jason McCarthy has given his Buy rating due to a combination of factors tied to Vyome’s lead program and financial position. He highlights that VT-1953, a topical gel for malignant fungating wounds, has generated robust Phase 2 data showing statistically significant improvement in malodor, pain, and quality of life versus vehicle, with no treatment-related safety issues, which strengthens the case for the drug’s clinical profile.
He also notes that the company is preparing to initiate a pivotal Phase 3 trial in a rare, severely underserved indication that currently lacks approved therapies, implying a sizable commercial opportunity exceeding $2B. In addition, Vyome’s existing cash balance, supplemented by available ATM capacity, appears sufficient to fund operations into mid-2027 and advance VT-1953 through key inflection points, leading him to view the shares as undervalued relative to the program’s de-risked outlook and upcoming catalysts.
McCarthy covers the Healthcare sector, focusing on stocks such as Aprea Therapeutics, Moleculin Biotech, and Plus Therapeutics. According to TipRanks, McCarthy has an average return of -14.2% and a 32.73% success rate on recommended stocks.